To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Speech in Commons Chamber - Mon 01 Sep 2014
Mitochondrial Replacement (Public Safety)

"It is a pleasure to follow the hon. Member for Stockton North (Alex Cunningham) who gave us that moving account of Jessica. That account has also raised other matters in relation to the principles and the ethics of the issues with which we are dealing. In 2008, I was involved …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Mitochondrial Replacement (Public Safety)
Speech in Commons Chamber - Mon 01 Sep 2014
Mitochondrial Replacement (Public Safety)

"My hon. Friend makes an important point. We recognise that this is not an uncontroversial technique similar to blood transfusion. It is controversial, and we must recognise that if we want to bring the public along with us. We must also recognise that, as my right hon. Friend the Member …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Mitochondrial Replacement (Public Safety)
Written Question
Cancer
Wednesday 18th June 2014

Asked by: David Burrowes (Conservative - Enfield, Southgate)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, in which single or multiple technology appraisals for pharmacological treatments for cancer the National Institute for Health and Care Excellence (NICE) has considered the sequential use of the appraised technology with another available treatment; and whether in each such appraisal this resulted in a recommendation on sequential use in each year since NICE was established.

Answered by Norman Lamb

The National Institute for Health and Care Excellence (NICE) has advised that providing all the information in the format requested would incur disproportionate cost.

Information about technology appraisals where NICE has recommended a technology only in circumstances in which a patient has not been treated with a previously recommended technology can be found within each published technology appraisal on NICE's website at:

www.nice.org.uk

Information about where NICE has considered or made recommendations regarding the sequential use of technologies can also be found within each published technology appraisal on the website.

Written Question
Medical Treatments
Wednesday 18th June 2014

Asked by: David Burrowes (Conservative - Enfield, Southgate)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence has recommended only for patients who have not been treated with a previously appraised drug.

Answered by Norman Lamb

The National Institute for Health and Care Excellence (NICE) has advised that providing all the information in the format requested would incur disproportionate cost.

Information about technology appraisals where NICE has recommended a technology only in circumstances in which a patient has not been treated with a previously recommended technology can be found within each published technology appraisal on NICE's website at:

www.nice.org.uk

Information about where NICE has considered or made recommendations regarding the sequential use of technologies can also be found within each published technology appraisal on the website.

Written Question
Cancer
Wednesday 18th June 2014

Asked by: David Burrowes (Conservative - Enfield, Southgate)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what (a) pharmacological treatments and (b) associated indications the National Institute for Health and Care Excellence (NICE) has recommended for (i) prostate cancer, (ii) lung cancer, (iii) bowel cancer, (iv) breast cancer and (v) kidney cancer through either single or multiple technology appraisals and under the end of life criteria in each year since NICE was established.

Answered by Norman Lamb

The consideration of end of life criteria was introduced into the National Institute for Health and Care Excellence's (NICE) technology appraisal process in January 2009. NICE has advised that it has recommended the following treatments for prostate, lung, bowel and kidney cancer under its technology appraisal programme where the end of life criteria were applied. No treatments for breast cancer have been recommended under the end of life criteria.

Cancer

Appraisal

Technolo-gy appraisal

Prostate

abiraterone in combination with prednisone or prednisolone for the treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen

TA259

Lung

oral topotecan for small cell lung cancer

TA184

pemetrexed (maintenance treatment) for non-small cell lung cancer

TA190

Bowel

sunitinib for gastrointestinal stromal tumours

TA179

Kidney

sunitinib (first-line) for renal cell carcinoma

TA169

pazopanib for the first-line treatment of advanced renal cell carcinoma

TA215

Source: National Institute for Health and Care Excellence

Speech in Commons Chamber - Mon 10 Mar 2014
Care Bill [Lords]

"I, too, have had experience of being in a police station, as a duty solicitor in my case, and therefore have seen for myself that the very last place these most vulnerable of people should be is a police station. Given that the Government have made commitments—indeed, financial commitments—on a …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Care Bill [Lords]
Speech in Westminster Hall - Wed 05 Mar 2014
Adult Autism Strategy

"I thank my hon. Friend for his extraordinary leadership and for having a positive impact in a relatively short time on the understanding of autism. On Asperger’s, he will share my concern for those who unfortunately fall into the criminal justice system, but how far do we need to go …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Adult Autism Strategy
Speech in Westminster Hall - Wed 05 Mar 2014
Adult Autism Strategy

"On incentivising employers and leading by example, the Government, in the NHS, are among the biggest employers around and will no doubt want to be an autism-friendly organisation and employer. Does the Minister have any information about how autism-friendly the NHS is in employing people with autism? Will he look …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Adult Autism Strategy
Speech in Commons Chamber - Wed 30 Oct 2013
Changes to Health Services in London

"Are there not three lessons to learn from the Secretary of State’s statement and the response from the shadow Secretary of State? First, we should listen to the opinions of local doctors. Secondly, delay puts at risk patient safety. Thirdly, we should not play politics. For Enfield, is it not …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Changes to Health Services in London
Speech in Commons Chamber - Tue 22 Oct 2013
Oral Answers to Questions

"Does the Minister recognise that the question is not if the changes take place, but when? Does he recognise that all my local doctors say that it is in the best health interests to get on with the changes, not least given that the £200 million invested in the new …..."
David Burrowes - View Speech

View all David Burrowes (Con - Enfield, Southgate) contributions to the debate on: Oral Answers to Questions